Scinai Immunotherapeutics Ltd.

SCNI

US09073Q2049

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 09:51:35 2024-04-29 am EDT			5-day change	1st Jan Change
0.44 ^USD	-3.89%		-4.14%	-26.10%

Apr. 08	Exchange-Traded Funds, Equity Futures Gain Slightly Pre-Bell Monday as June Rate Cut Likelihood Falls	MT
Apr. 08	Ayana Pharma Selects Scinai Immunotherapeutics' CDMO Unit to Provide Drug Development and cGMP Manufacturing Services	CI

Scinai Immunotherapeutics Ltd. announced that it has received $1.329254 million in funding

October 02, 2023

On October 3, 2023, Scinai Immunotherapeutics Ltd. closed the transaction. The transaction included participation from a single investor

Latest news about Scinai Immunotherapeutics Ltd.

Exchange-Traded Funds, Equity Futures Gain Slightly Pre-Bell Monday as June Rate Cut Likelihood Falls	Apr. 08	MT
Ayana Pharma Selects Scinai Immunotherapeutics' CDMO Unit to Provide Drug Development and cGMP Manufacturing Services	Apr. 08	CI
Scinai Immunotherapeutics Ltd. Appoints Liat Halpert as Head of Business Development and Sales	Feb. 13	CI
Scinai Immunotherapeutics Ltd. announced that it has received $1.694259 million in funding	Jan. 11	CI
Transcript : Scinai Immunotherapeutics Ltd. - Special Call	Jan. 09
Scinai Immunotherapeutics Exercises Outstanding Warrants for $1.69 Million in Proceeds	Dec. 29	MT
Scinai Immunotherapeutics Ltd. announced that it expects to receive $1.694259 million in funding	Dec. 28	CI
Scinai Immunotherapeutics Ltd. Extends Maturity of Its Finance Facility with Scinai Immunotherapeutics from 2027 to 2031	Nov. 29	CI
Scinai Immunotherapeutics Regains Compliance With Nasdaq's Shareholder Equity Rule	Nov. 20	MT
Scinai Immunotherapeutics Ltd. Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting Its New CDMO Business Unit	Nov. 06	CI
European Investment Bank Considers Extending Maturity of Scinai Immunotherapeutics Ltd. of its Financial Facility Contract	23-10-31	CI
Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-31	CI
ADRs Hold Steady, Medigus Ltd. Climbs 24.5%	23-10-09	DJ
Scinai Immunotherapeutics Ltd. announced that it has received $1.329254 million in funding	23-10-02	CI
Scinai Immunotherapeutics Closes $1.3 Million Registered Direct Offering	23-09-20	MT
Scinai Immunotherapeutics Ltd. announced that it expects to receive $1.329254 million in funding	23-09-18	CI
ADRs Close Lower, Scinai Immunotherapeutics Ltd. Declines 15.5%	23-09-15	DJ
Scinai Immunotherapeutics Launches $1.33 Million Registered Direct Offering	23-09-15	MT
ADRs Advance, Brainsway Ltd. Climbs 14.0%	23-09-14	DJ
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	23-09-06	MT
BiondVax Pharmaceuticals Changes Name to Scinai Immunotherapeutics	23-09-06	MT
BiondVax Pharmaceuticals Ltd. has Changed its Name to Scinai Immunotherapeutics Ltd	23-08-24	CI
BiondVax Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
ADRs End Mostly Lower, BiondVax, Evaxion Biotech Trade Actively	23-06-05	DJ
Top Premarket Gainers	23-06-05	MT

Chart Scinai Immunotherapeutics Ltd.

Duration

Period

More charts

Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Companyâs core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

Sector

Biotechnology & Medical Research

Calendar

2024-04-29 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.4578 USD

Average target price

70 USD

Spread / Average Target

+15,189.45%

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SCINAI IMMUNOTHERAPEUTICS LTD.	-26.10%	1.99M
IQVIA HOLDINGS INC.	+2.41%	42.75B
LONZA GROUP AG	+47.87%	41.61B
MODERNA, INC.	+12.37%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.47%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.67%	18.12B
MEDPACE HOLDINGS, INC.	+30.52%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.56%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.09%	11B

Other Biotechnology & Medical Research